Semaglutide: $79/mo, month-to-month Tirzepatide: $129/mo, month-to-month Locked in for the life of your plan
Experience safe, significant and rapid weight loss with our GLP-1 agonist-based medical weight loss program
Tirzepatide (Mounjaro) is a dual agonist targeting both GLP-1 and GIP receptors, which tends to produce greater weight loss
Whilst the US Food and Drug Administration (FDA) has approved five drug therapies to treat obesity (orlistat, phentermine/topiramate, lorcaserin, naltrexone/bupropion, liraglutide), the European Medicines Agency (EMA) has approved only three drug therapies (orlistat, bupropion/naltrexone and liraglutide) [8] at the time of writing
What are the benefits of proper hydration during GLP-1 treatment
take control